| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
The Oncologist 2002;7:13-19
On page 15, in Table 1, the regimen identified for the Jassem et al. trial was erroneous. AD (doxorubicin and docetaxel) versus FAC should be AP (doxorubicin and paclitaxel) versus FAC.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |